CAMA-1 Cell Line

Tool Details

*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)

• Name: CAMA-1 Cell Line
• Cancer: Breast cancer
• Organism: Human
• Gender: Female
• Tissue: Breast; Mammary gland
• Donor: This cell line was established in 1975 from the pleural effusion of a 51-year-old Caucasian female with malignant adenocarcinoma of the breast.
• Morphology: Epithelial
• Growth properties: Adherent, patchy
• Model: Tumourigenic
• Model description: Tumourigenic in nude mice
• Products or characteristics of interest: Karyotype: modal number = 80; range = 68 to 83. This is a hypertriploid human cell line with the modal chromosome number of 80 occurring in 44% of a total of 88 cells examined. The rate of polyploid cells was 3.5%. Karyotypes of this cell line were generally uniform and stable. There were 12-13 marker chromosomes per cell, 11 of which were found in all cells, and 7 of which were mostly paired. Among the markers were paired mar(1qter--q21::?::6p11.2--6pter), t(3q::?), and i(16q); single der(12)t(12;?)(q24:?); and 8-9 others. Double minutes occurred in some cells; however, they were present as only one or two copies per cell. Structurally normal N16 was absent and N8 occurred in only a few cells. Paired normal X chromosomes were present in every cell. Isoenzymes: AK-1, 1; ES-D, 1-2; G6PD, B; GLO-I, 1-2; Me-2, 1; PGM1, 1; PGM3, 1
• Description: CAMA-1 is a luminal-type human breast cancer cell line that displays rounded morphology in adherent tissue culture. These cells are considered Her2-negative and oestrogen-receptor/progesterone-receptor (ER/PR)-positive. They are responsive to oestrogen and sensitive to growth inhibition by tamoxifen. The CAMA-1 cells have an in-frame mutation in the E-cadherin gene, resulting in a truncated, non-functional protein. In addition, they have oncogenic mutations in PTEN and p53 and amplification of the cyclin D1 gene.
• Application: 3D cell culture
• Biosafety level: 1
• Additional notes: The cells form poorly differentiated grade III tumours consistent with breast carcinoma.

Target Details

• Target: Antigen expression: Blood type O; Rh +; HLA A10, A11, B12, B18

Applications

• Application: 3D cell culture

Handling

• Passage number: An ampule frozen in May of 1978 at passage 21 was provided to the ATCC in June of 1991.
• Growth medium: EMEM supplemented with FBS to a final concentration of 10%
• Temperature: 37° C
• Atmosphere: 5% CO2 in air
• Shipping conditions: Dry Ice
• Storage medium: Complete growth medium supplemented with 5% (v/v) DMSO
• Storage conditions: Vapor phase of liquid nitrogen
• Str profiling: Amelogenin: XCSF1PO: 10,12D13S317: 12D16S539: 11D5S818: 12,13D7S820: 8,11TH01: 8,9.3TPOX: 8vWA: 15D3S1358: 18D21S11: 32.2D18S51: 14,15Penta_E: 12,14Penta_D: 10,11D8S1179: 12,13FGA: 19,25D19S433: 13D2S1338: 17,21

References

• Ji et al. 1994. Journal of Cellular Biochemistry. 54: 332-342. PMID: 8200913.
• Van Horssen et al. 2012. Breast Cancer Research and Treatment. 136: 365-377. PMID: 23053649.